Anti-Cancer Drug Prices to Drop from November 9; Consumers to Save ₹3,502 Crore Annually
The revised prices of 1,225 anti-cancer medicine formulations will come into effect from November 9, 2026. The government’s price regulation has led to reductions in 1,031 formulations, with around 600 brands recording price cuts of more than 50%. The highest reduction stands at 96.45%. Consumers are expected to save approximately ₹3,502 crore annually.
Anti-Cancer Drug Prices to Drop from November 9; Consumers to Save ₹3,502 Crore Annually
CNB WORLD TIMES
The prices of several anti-cancer medicines will come down from November 9, 2026, following the government's decision to regulate trade margins on these drugs. The move is expected to provide major financial relief to cancer patients and their families, with estimated annual savings of ₹3,502.31 crore.
The National Pharmaceutical Pricing Authority (NPPA), under the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, has capped trade margins at 30% on the Maximum Retail Price (MRP) of 137 anti-cancer drugs. The decision was taken based on the recommendations of an expert committee constituted by the Directorate General of Health Services (DGHS).
According to the NPPA, 76 pharmaceutical companies have reported revised prices for 1,225 formulations covering 121 anti-cancer drugs. Out of these, 1,031 formulations have reported a reduction in MRP. Around 600 brands have recorded price reductions of more than 50%, while the highest reduction is 96.45%.
The remaining 10 to 15 identified drugs that have not yet been launched in India will also come under the trade margin regulation when they enter the market.
The government said the move aims to make essential anti-cancer medicines more affordable and accessible to patients. The notification issued on October 17, 2026, will remain in force until further orders. However, manufacturers can increase prices annually as permitted under the Drugs (Prices Control) Order, 2013, while maintaining the maximum permissible trade margin of 30%.
Revised Price Lists and Consumer Complaints
All retailers, dealers, hospitals and medical institutions must prominently display the revised MRP lists on their websites and premises. State Drug Controllers will monitor compliance by manufacturers, dealers, hospitals and medical institutions.
Consumers can check the revised prices through the Pharma Sahi Daam mobile application and the NPPA website: www.nppa.gov.in. They can also report violations through the following channels:
- Email: monitoring-nppa[at]gov[dot]in
- Helpline: 1800-11-1255
- Postal Address: Deputy Director, Monitoring, NPPA, 3rd Floor, YMCA Cultural Centre Building, 1 Jai Singh Marg, New Delhi – 110001.
The revised prices are expected to reduce the financial burden on cancer patients and improve access to essential cancer treatment.
List of major anti-cancer brands with revised prices
|
Formulation |
Brand Name |
Company Name |
Old MRP (₹) |
Revised MRP (₹) |
|
Bevacizumab 100 MG Injection: Used for Lung, Colon, Ovary and Cervical Cancer |
Bryxta |
Zydus Lifesciences Limited |
25,995.00 |
3,318.00 |
|
BevaciRel |
Reliance Life Sciences Private Limited |
24,079.00 |
3,985.00 |
|
|
CIZUMAB |
HETERO HEALTHCARE LTD |
15,658.00 |
3,103.00 |
|
|
Versavo |
Dr. Reddys Laboratories Limited |
7,686.00 |
3,504.23 |
|
|
Denosumab 60 MG Injection: Used for breast and prostate cancer (prevents bone loss) |
DenOsteoRel |
Reliance Life Sciences Private Limited |
24,955.00 |
6,240.00 |
|
Debrumab |
RPG LIFE SCIENCES LTD |
22,031.25 |
5,941.00 |
|
|
Denoclast |
Zydus Lifesciences Limited |
19,687.50 |
7,334.84 |
|
|
ROZEL |
INTAS PHARMACEUTICALS LTD |
15,458.40 |
6,825.50 |
|
|
Abiraterone acetate 250 MG Tablet: Used for Prostate Cancer |
ABIRONE |
ARVINCARE PHARMA PVT LTD |
41,250.00 |
3,218.23 |
|
ABIRAT |
Khandelwal Laboratories Private Limited |
36,088.81 |
4,064.48 |
|
|
AHABIR |
HETERO HEALTHCARE LTD |
33,876.50 |
4,925.00 |
|
|
Abirapro |
Glenmark Pharmaceuticals Ltd. |
28,744.00 |
5,768.00 |
|
|
Pegfilgrastim 6 MG Injection: To prevent neutropenia in cancer patients |
PEG FILTERO |
HETERO HEALTHCARE LTD |
9,093.00 |
1,631.00 |
|
Peg-ReliGrast |
Reliance Life Sciences Private Limited |
5,331.00 |
1,258.00 |
|
|
Pegex |
Gennova Biopharmaceuticals Ltd. |
6,270.45 |
1,527.78 |
|
|
Peg Frastim |
RPG LIFE SCIENCES LTD |
6,660.85 |
1,807.00 |
|
|
Azacitidine 100 MG Injection: Used for Blood Cancer |
AzatiRel |
Reliance Life Sciences Private Limited |
7,790.00 |
1,397.00 |
|
AZADINE |
INTAS PHARMACEUTICALS LTD |
5,964.70 |
1,199.50 |
|
|
Azacytin |
Dr. Reddys Laboratories Limited |
6,337.00 |
1,495.04 |
|
|
Azadual 100 |
MSN LABORATORIES PRIVATE LIMITED |
4,852.03 |
1,207.80 |
|
|
Enzalutamide 40 MG Capsule: Used for prostate cancer |
ENZAPTOR 40 |
HALSTED PHARMA PVT LTD |
20,625.00 |
2,475.60 |
|
XTIDE |
ERIS LIFESCIENCES LIMITED |
10,828.12 |
1,729.21 |
|
|
Enzuta |
Emcure Pharmaceuticals Ltd. |
20,667.00 |
4,157.65 |
|
|
ENZAMIDE |
INTAS PHARMACEUTICALS LTD |
10,781.25 |
3,536.50 |
|
|
Fulvestrant 250 mg Injection: Used for breast cancer |
FASNORM |
ERIS LIFESCIENCES LIMITED |
30,421.87 |
3,671.73 |
|
FULZOS |
HETERO HEALTHCARE LTD |
16,500.00 |
3,215.00 |
|
|
Fulvira |
Emcure Pharmaceuticals Ltd. |
16,694.95 |
3,900.41 |
|
|
FISTENT INJ |
Adley Formulations Pvt.Ltd |
22,600.00 |
6,031.50 |
|
|
Palbociclib 125 MG Capsule: Used for breast cancer |
Palbopro |
RPG LIFE SCIENCES LTD |
40,421.33 |
2,720.00 |
|
PALBOMED |
Medicamen Biotech Limited |
13,500.00 |
2,302.00 |
|
|
PICLIB |
HETERO HEALTHCARE LTD |
7,801.50 |
2,058.00 |
|
|
Palborest 125 |
MSN LABORATORIES PRIVATE LIMITED |
2,246.00 |
791.80 |
|
|
Pemetrexed 500 MG Vial: Used for lung cancer |
ReliTrexed |
Reliance Life Sciences Private Limited |
9,977.00 |
1,113.00 |
|
PEMETOMED |
Medicamen Biotech Limited |
5,062.00 |
940.00 |
|
|
ADPEM 500 |
Adley Formulations Pvt.Ltd |
5,499.00 |
1,035.05 |
|
|
Pemgem |
Dr. Reddys Laboratories Limited |
7,032.00 |
3,408.64 |
|
|
Pertuzumab 420 MG Injection: Used for breast cancer |
LUPIHER 2 |
Lupin Limited |
83,520.00 |
37,358.35 |
|
Womab |
Dr. Reddys Laboratories Limited |
74,992.50 |
53,708.19 |
What's Your Reaction?
